CryoCath Completes Sale to ATS Medical
Montreal, Quebec, Canada - June 28, 2007 - CryoCath Technologies Inc. (TSX:CYT), the global leader in cryotherapy products
to treat cardiac arrhythmias, today announced it has completed the sale of its
surgical portfolio to ATS Medical in a cash transaction valued at US$22 million.
With milestone payments, the agreement could increase in value to reach a total
of US$30 million.
About Medtronic CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the
world in cryotherapy products to treat cardiovascular disease. With a priority
focus on providing physicians with a complete solution of catheter products to
treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S.,
across Europe and several ROW countries. The Company is developing additional
products to expand its pipeline of products to treat cardiac
For further information, please contact: